Navigation Links
DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Date:8/19/2007

r absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based on DJO's and ReAble's current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to, the occurrence of any event, change or other circumstance that could give rise to a termination of the merger agreement; the outcome of any legal proceedings that may be instituted against DJO, ReAble or others following the announcement of the merger agreement, the inability to complete the merger due to the failure to obtain stockholder approval or the failure to satisfy other conditions to the merger, including receiving applicable foreign regulatory approvals relating to the transaction; the failure to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the merger; risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger. Other risk factors are detailed in the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2007, filed on August 3, 2007, with the Securities and Exchange Commission and ReAble's Quarterly Report on Form 10-Q for the three months ended June 30, 2007, filed on August 14, 2007, with the Securities and Exchange Commission. Many of the factors that will determine the outcome of the subject matter of this press release are beyond DJO's and ReAble's ability to control or predict.

DJO Investor/Media Contact:

DJO Incorporated

Mark Francois, Director of Investor Relations

(760) 734-4766


SOURCE ReAble Therapeutics Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Doyle urges support of higher education spending
2. Doyle outlines spending for Medical College, UWM
3. Chippewa Valley to get $46 million in defense spending
4. In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde
5. Audit of multi-million dollar state IT spending will proceed
6. Stratagene sets aside $21M to pay Third Wave pending appeal
7. New report says Wisconsin R&D spending exceeding expectations
8. IT Spending to Increase in Second Half of 2003
9. Technology and mergers: Getting the strategic applications
10. AT&T - BellSouth merger: Revestiture continues
11. CDW names VP to handle Berbee merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015  For about a century, a ... ability to utilize and catabolize glucose at a ... is called the ,Warburg phenomenon", that is an ... oxygen presence, leading to enhanced lactate generation. Even ... choose glucose fermentation. A variety of such abnormalities ...
(Date:4/27/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... year ended December 31, 2014. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... provide the outcome management and investors had hoped ... Therapeutics", said Andrew Rae , President & ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... patente para un nuevo receptor utilizando tecnología de descubrimiento ... no cubierta en el tratamiento de millones de pacientes ... anunciado hoy que ha recibido una patente en Europa ... el descubrimiento de Molecular Health de que EPHB4 es ...
(Date:4/27/2015)... Calif. (PRWEB) April 27, 2015 Dr. ... drug and chemical toxicity carries implications for advancing the ... April 28 at National University , the second-largest ... presentation by Dr. Hanzlik, a professor at the University ... metabolism and drug design, starts at 5 p.m. and ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... BOSTON, Jan. 11, 2012  CBI, a division of Advanstar ... 11th Annual Patient Adherence Forum, which is being held ... in Philadelphia, PA. At the event, industry experts share ... through stakeholder collaboration and patient engagement.  ...
... 11, 2012 What:  Come view ... CES, and hear Lucier and Rothberg discuss the future of ... http://photos.prnewswire.com/prnh/20110216/MM49339LOGO ) When:   Wednesday, ... Where:   Las Vegas Convention Center, North Hall, Booth ...
... 11, 2012  Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), which ... Dr. J. Joseph Kim, President and CEO, will present an overview of ... Noble Financial 8th Annual Equity Conference January ...   Inovio Presentation Tuesday, ...
Cached Biology Technology:Complete Agenda Announced for 11th Annual Patient Adherence Forum 2Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference 2Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference 3
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... world,s first controlled study of a comprehensive genetic screening test ... twin girls born in Germany in June and a singleton ... in a pilot study of comparative genomic hybridisation (CGH) by ... a full range of chromosomal disorders. Dr Cristina ...
... Rivers and streams supply the lifeblood of ecosystems across the ... well as a wide array of life forms in rivers ... the fish humans eat. But humans and nature itself are ... role to support fish species, according to new research by ...
... global energy demands is the use of Poplar, a ... the most out of Poplar plantations, varieties that are ... or higher yields, for exampleare desired. But do these ... populations of Poplar? In particular, is the genetic makeup ...
Cached Biology News:First babies born from genetic screening study 2First babies born from genetic screening study 3A river ran through it 2A river ran through it 3A river ran through it 4The risks and benefits of using poplars for biofuels 2
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Request Info...
Biology Products: